LIGAND PHARMACEUTICALS INC — Director's Dealing 2021

Feb 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2021-02-09

Reporting Person: Sabba Stephen L (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-09	Common Stock	M	7335	$10.12	Acquired	31766	Direct
2021-02-09	Common Stock	M	7335	$12.53	Acquired	39101	Direct
2021-02-09	Common Stock	S	556	$208.00	Disposed	38545	Direct
2021-02-09	Common Stock	S	14114	$208.55	Disposed	24431	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-09	Non-Qualified Stock Option (right to buy)	$10.12	M	7335	Disposed	2021-06-01	Common Stock (7335)	Direct
2021-02-09	Non-Qualified Stock Option (right to buy)	$12.53	M	7335	Disposed	2022-05-31	Common Stock (7335)	Direct

Footnotes

F1: These securities, as represented in Column 5, include a grant of 831 restricted shares approved by the Board of Directors of the Company at the 2020 Meeting, which shares were previously reported on a Form 4 for this Reporting Person filed on June 12, 2020, and are included on this Form 4 only to report that they will vest in full within six (6) months from the date hereof.

F2: These securities, as represented in Column 5, were acquired by a grant of 7,335 shares approved by the Board of Directors of the Company at the 2011 Meeting and are fully vested and exerciseable as more fully described on a Form 4 for this Reporting Person filed on June 6, 2011.

F3: These securities, as represented in Column 5, were acquired by a grant of 7,335 shares approved by the Board of Directors of the Company at the 2012 Meeting and are fully vested and exerciseable as more fully described on a Form 4 for this Reporting Person filed on June 4, 2012.